RECURRENT NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Target immune therapy enters human trials for aggressive blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack three different proteins (CD19, CD20, and CD22) found on cancer cells. It is for adults with certain aggressive blood cancers like non-Hodgkin lymphoma, acute lymphob…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for kids with tough cancers: experimental drug trial opens
Disease control Recruiting nowThis study is testing a new drug called tegavivint in children, teens, and young adults whose solid tumors or lymphomas have come back or haven't responded to other treatments. The main goals are to find the safest dose, understand the side effects, and see if the drug can help s…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Custom immune cells fight blood cancers after transplant
Disease control Recruiting nowThis study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New CAR-T therapy trial targets Tough-to-Treat HIV-Related cancers
Disease control Recruiting nowThis early-stage study is testing a personalized immune therapy called axicabtagene ciloleucel (a type of CAR-T) for people with HIV who have an aggressive form of B-cell lymphoma that has returned or not responded to prior treatments. The main goals are to check if the treatment…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC